Phosphatidylinositol 3-kinase in breast cancer: Where from here?

Clinical Cancer Research

Volumn 13, Issue 20, 2007, Pages 5988-5990

  Angelo, Paradiso ^a   Anita, Mangia ^a   Amalia, Azzariti ^a   Stefania, Tommasi ^a  

^a NATIONAL CANCER INSTITUTE GIOVANNI PAOLO II   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; DOXORUBICIN; GEMCITABINE; GUANOSINE TRIPHOSPHATASE ACTIVATING PROTEIN; IC 87114; KL 147; PACLITAXEL; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; POLYPHOSPHOINOSITIDE; PROTEIN KINASE B; PROTEIN P110; PX 866; RAS PROTEIN; SF 1126; UNCLASSIFIED DRUG; VYRIDIN DERIVATIVE; WORTMANNIN; XL 147;

BREAST CANCER; CELL GROWTH; CELL PROLIFERATION; CELL SURVIVAL; CHROMOSOME 10; CHROMOSOME 3Q; ENZYME MECHANISM; ENZYME SUBUNIT; GENE; HUMAN; HUMAN CELL; NOTE; PI3K GENE; PI3KCA GENE; PRIORITY JOURNAL;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ANIMALS; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; DIMERIZATION; ENZYME INHIBITORS; EXONS; HUMANS; MODELS, BIOLOGICAL; MUTATION; NUCLEAR PROTEINS; SIGNAL TRANSDUCTION; TRANSCRIPTION FACTORS;

EID: 35948980814     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-07-1106     Document Type: Note

References (25)

1. Dillon RL, White DE, Muller WJ. The phosphatidyl inositol 3-kinase signaling network: implications for human breast cancer. Oncogene 2007;26:1338-45.
2. Bader AG, Kang S, Zhao L, Vogt PK. Oncogenic PI3K deregulates transcription and translation. Nat Rev Cancer 2005;5:921-9.
3. Reshkin SJ, Bellizzi A, Albarani V, et al. Phosphoinositide 3-kinase is involved in the tumor-specific activation of human breast cancer cell Na(+)/H(+) exchange, motility, and invasion induced by serum deprivation. J Biol Chem 2000;275:5361-9.
4. McCubrey JA, Steelman LS, Chappell WH, et al. Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance. Biochim Biophys Acta 2006;1773:1263-84.
5. Saal LH, Holm K, Maurer M, et al. PIK3CA mutations correlate with hormone receptors, node metastasis, and ERBB2, and are mutually exclusive with PTEN loss in human breast carcinoma. Cancer Res 2005;65:2554-9.
6. Karakas B, Bachman KE, Park BH. Mutation of the PIK3CA oncogene in human cancers. Br J Cancer 2006;94:455-9.
7. Li SY, Rong M, Grieu F, Iacopetta B. PIK3CA mutations in breast cancer are associated with poor outcome. Breast Cancer Res Treat 2006;96:91-5.
8. Maruyama N, Miyoshi Y, Taguchi T, Tamaki Y, Monden M, Noguchi S. Clinicopathologic analysis of breast cancers with PIK3CA mutations in Japanese women. Clin Cancer Res 2007;13:408-14.
9. Barbareschi M, Buttitta F, Felicioni L, et al. Different prognostic role of mutations in the helical and kinase domains of the PIK3CA gene in breast carcinomas. Clin Cancer Res 2007;13:6064-79.
10. Tokunaga E, Kimura Y, Mashino K, et al. Activation of PI3K/Akt signaling and hormone resistance in breast cancer. Breast Cancer 2006;13:137-44.
11. Liang K, Lu Y, Li X, et al. Differential roles of phosphoinositide- dependent protein kinase-1and akt1 expression and phosphorylation in breast cancer cell resistance to paclitaxel, doxorubicin, and gemcitabine. Mol Pharmacol 2006;70:1045-52.
12. Janssen EA, Soiland H, Skaland I, et al. Comparing the prognostic value of PTEN and Akt expression with the mitotic activity index in adjuvant chemotherapy-treated node-negative breast cancer patients aged <55 years. Cell Oncol 2007;29:25-35.
13. Samuels Y, Diaz LA, Jr., Schmidt-Kittler O, et al. Mutant PIK3CA promotes cell growth and invasion of human cancer cells. Cancer Cells 2005;7:561-73.
14. Volpi A, Nanni O, De Paola F, et al. HER-2 expression and cell proliferation: prognostic markers in patients with node-negative breast cancer. J Clin Oncol 2003;21:2708-12.
15. Pawlowski V, Revillion F, Hebbar M, Hornez L, Peyrat JP. Prognostic value of the type I growth factor receptors in a large series of human primary breast cancers quantified with a real-time reverse transcription-polymerase chain reaction assay. Clin Cancer Res 2000;6:4217-25.
16. Tsutsui S, Inoue H, Yasuda K, et al. Reduced expression of PTEN protein and its prognostic implications in invasive ductal carcinoma of the breast. Oncology 2005;68:398-404.
17. Schmitz KJ, Otterbach F, Callies R, et al. Prognostic relevance of activated Akt kinase in node-negative breast cancer: a clinicopathological studyof 99 cases. Mod Pathol 2004;17:15-21.
18. Rojo F, Najera L, Lirola J, et al. 4E-binding protein 1, a cell signaling hallmark in breast cancer that correlates with pathologic grade and prognosis. Clin Cancer Res 2007;13:81-9.
19. van der Hage JA, van den Broek LJ, Legrand C, et al. Overexpression of P70 S6 kinase protein is associated with increased risk of locoregional recurrence in node-negative premenopausal early breast cancer patients. Br J Cancer 2004;90:1543-50.
20. Stein RC. Prospects for phosphoinositide 3-kinase inhibition as a cancer treatment. Endocr Relat Cancer 2001;8:237-48.
21. Ferry DR, Smith A, Malkhandi J, et al. Phase I clinical trial of the flavonoid quercetin: pharmacokinetics and evidence for in vivo tyrosine kinase inhibition. Clin Cancer Res 1996;2:659-68.
22. Gharbi SI, Zvelebil MJ, Shuttleworth SJ, et al. Exploring the specificity of the PI3K family inhibitor LY294002. Biochem J 2007;404:15-21.
23. Ward SG, Finan P. Isoform-specific phosphoinositide 3-kinase inhibitors as therapeutic agents. Curr Opin Pharmacol 2003;3:426-34.
24. Lee JT, Jr., Steelman LS, McCubrey JA. Phosphatidylinositol 3′-kinase activation leads to multidrug resistance protein-1expression and subsequent chemoresistance in advanced prostate cancer cells. Cancer Res 2004;64:8397-404.
25. 2-terminal kinase pathways: an effective therapeutic strategy for lung cancer. Clin Cancer Res 2005;11:6065-74.